FIELD: preservatives for metal-working or paper industry; preparation of varnishes and paints.
SUBSTANCE: hardening temperature of proposed compound is not above -10°C; compound contains the following components, mass-%: one or several phenolates, 50-80; crystallization inhibitor, 0.1-10; water and other components possessing biocide action. Used as phenolates in compound are phenol salts and/or phenolates having one or several aliphatic and/or aromatic substituents, ortho-phenyl phenolates, halogenated substituted phenolates, cresol salts, resorcine salts, etc. Method of preparation of phenolate-containing compound consists in filling the container with water and neutralizing agent, dissolving phenol compounds and addition of crystallization inhibitor. Dissolving temperature is 5-80°C, preferably 40-60°C. Used as crystallization inhibitor is one or several compounds of aliphatic glycols, such as ethylene glycol, monopropylene glycol and/or diethylene glycol and/or one or several aliphatic or aromatic alcohols in the amount of 1-3 mass-% in compound containing 60-70 mass-% of phenolate. Aqueous preservative suspension or dispersion of minerals and/or fillers and/or pigments includes compound in the amount of from 10 g/t to 250 g/t of suspension or dispersion.
EFFECT: low freezing point of compound.
21 cl, 22 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION OF CARBOXAMIDE INHIBITORS OF HIV INTEGRASE, CONTAINING COMPOSITION WITH CONTROLLED RATE OF RELEASE | 2005 |
|
RU2382648C2 |
METHOD OF PRODUCING A PYRAZOLAMIDE COMPOUND | 2017 |
|
RU2736722C2 |
METHOD OF CONSERVING WATER PREPARATIONS OF MINERAL SUBSTANCES, CONSERVED WATER PREPARATIONS OF MINERAL SUBSTANCES AND APPLICATION OF CONSERVING COMPOUNDS IN WATER PREPARATIONS OF MINERAL SUBSTANCES | 2011 |
|
RU2529816C2 |
AQUEOUS PHARMACEUTICAL SUSPENSION CONTAINING REBAMIPIDE, AND METHOD FOR PREPARING IT | 2007 |
|
RU2467751C2 |
AQUEOUS OPHTHALMIC SUSPENSION OF CRYSTAL REBAMIPIDE | 2005 |
|
RU2398585C2 |
PREPARATION AND CRYSTALLISATION OF S-[2-[1-(2-ETHYLBUTYL) CYCLOHEXYLCARBONYLAMINO]-PHENYL]-2-METHYLTHIOPROPIONATE | 2010 |
|
RU2523280C2 |
APPLICATION OF ATASANAVIR FOR IMPROVEMENT OF PHARMAKINETICS OF UGT1A1-METABOLISED MEDICATIONS | 2005 |
|
RU2403066C2 |
METHOD FOR PREPARING UREA-CONTAINING SILANES | 2015 |
|
RU2679800C2 |
3,7-DIAZABICYCLO[3,3,1]-CONTAINING PREPARATIONS AS ANTI-ARRHYTHMIC COMPOUNDS | 2002 |
|
RU2286993C2 |
Authors
Dates
2007-05-10—Published
2001-04-26—Filed